Comparative effectiveness of anti-fibrosis treatment in patients after HCV infection and in patients with non-alcoholic fatty liver disease (NAFLD)
DOI:
https://doi.org/10.12775/JEHS.2021.11.02.022Keywords
posthepatic fibrosis, NAFLD, overweight, elastography, index NFS, bicyclolAbstract
Due to the high prevalence of NAFLD and CHC, these two pathologies will progress and contribute to the progression of fibrosis. Unfortunately, nowadays there is no single treatment strategy for such patients. That is why, in most cases a variety of treatment regimens on the base of different hepatoprotectors are prescribed. Instead, there is evidence that the use of some hepatoprotectors has no influence on fibrotic processes in the liver or can even exacerbate them. In order to study the antifibrotic effect of hepatoprotectors in patients with posthepatic fibrosis after HCV infection and in patients with NAFLD, we studied the results of prescribing the hepatoprotective drug bicyclol.
References
World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. –2018.
Williams, C.D. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study / C.D. Williams [et al.] // Gastroenterology. – 2011. – № 140. – P. 124–131.
Havrylyuk N.M., Hospodars'kyy I.Ya., Prokopchuk O.V., Havrylyuk M.Ye. Otsinka vplyvu nayavnosti u patsiyentiv nadlyshkovoyi masy tila na fibroz pechinky // Zdobutky klinichnoyi i eksperymental'noyi medytsyny. – 2020. – # 4. – S.50-60.
Adinolfi, L.E. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations / L.E. Adinolfi [et al.] // International Journal of Molecular Sciences. – 2016. – № 6 (17). – P. 803.
Amarapurka D.N. Non-alcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis / D.N. Amarapurka, A.D. Amarapurkar, N.D. Patel, Agal, R. Baigal, P. Gupte, S. Pramanik // Ann Hepatol. – 2006. – Vol.5. – P.30-33.
Patel, A. Hepatitis C virus infection and nonalcoholic steatohepatitis / A. Patel, S.A. Harrison // Gastroenterology & Hepatology. – 2012. – № 5 (8). – P. 305–312.28
Buyeverova E.L. Narusheniya lipidnogo obmena u bol’nykh s metabolicheskim sindromom / E.L. Buyeverova, O.M. Drapkina, V.T.Ivashkin // Ros. meditsin. vesti. – 2014. – T.19, № 2. – S. 23-32.
Khullar V. Pre-and-post transplant considerations in patients with non-alcoholic fatty liver disease / V. Khullar, A. Dolganiuc, R.J. Firpi // World J Transplant. – 2014. – Vol.4 (2). – P.81-92
Charlton M.R. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States / M.R. Charlton, J.M. Burns, R. A. Pedersen, K.D. Watt, J.K. Heimbach, R.A. Dierkhising // Gastroenterology. – 2011. – Vol. 141. – P.1249-1253.
Faustini A., Colais P., Fabrizi E. et al. Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups // BMC Infect. Dis. – 2010. – Vol. 10. – P. 97.
Gospodarskiy I.Ya., Volynets’ K.V., Grushko V.V. Osobennosti lecheniya bol’nykh gepatitom V i S pri soputstvuyushchiy krioglobulinemii // Ekcpepimental’naya i klinicheckaya fapmakologiya. – 2013. - № 12. – S. 34-37.
Ivanov A.V., Bartosch B., Smirnova O.A. HCV and Oxidative Stress in the Liver // Viruses. – 2013. – Vol. 5 (2). – P. 439–469.
Hawke R.L., Schrieber S.J., Soule T.A. Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C // J. Clin. Pharmacol. – 2010. – Vol. 50 (4): - P. 434–449.
Reddy K.R., Belle S.H. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C // Clin. Trials. – 2012. – Vol. 9 (1). – P. 102–112.
Kolesnikova E. V. Sovremennyy patsiyent s zabolevaniyem pecheni i patologiyey serdechno-sosudistoy sistemy: kakoy vybor sdelat’? // Suchasna gastroyenterologіya. - 2014. - № 2 (76) – S. 85-94.
Paris A.J., Snapir Z., Christopherson C.D.A Polymorphism that Delays Fibrosis in Hepatitis C Promotes Alternative Splicing of AZIN1, Reducing Fibrogenesis // Hepatology. – 2011. – Vol. 54(6). – P. 2198–2207.
Pharmacological therapy of non-alcoholic steatohepatitis / Ratzin et al. // Clin.Liver Dis. - 2009. – Vol. 13 (4). - P. 667-688.
Duong FH, Christen V, Filipowicz M, Heim MH. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro // Hepatology. – 2006. - Vol. 43 (4). – P. 796-806.
Lioznov D.A., Geyvandova N.I., Morozov V.G. Otsenka effektivnosti original’nogo gepatoprotektornogo preparata Bitsiklol u bol’nykh khronicheskim virusnym gepatitom S // Ukraїns’kiy medichniy chasopis. – 2014. - № 6 (104) . – S. 14-17.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 © The Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 496
Number of citations: 0
